- Home
- AIZ vs EXEL Comparison
AIZ vs EXEL Comparison
Compare AIZ & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AIZ | EXEL |
|---|---|---|
| Founded | 1892 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | AIZ | EXEL |
|---|---|---|
| Price | $222.87 | $44.36 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 24 |
| Target Price | ★ $249.17 | $44.73 |
| AVG Volume (30 Days) | 276.7K | ★ 2.5M |
| Earning Date | 11-04-2025 | 11-04-2025 |
| Dividend Yield | ★ 1.58% | N/A |
| EPS Growth | 17.21 | ★ 53.55 |
| EPS | ★ 16.41 | 2.38 |
| Revenue | ★ $12,568,700,000.00 | $2,288,218,000.00 |
| Revenue This Year | $8.50 | $9.14 |
| Revenue Next Year | $5.73 | $12.51 |
| P/E Ratio | ★ $13.58 | $18.67 |
| Revenue Growth | 6.92 | ★ 9.93 |
| 52 Week Low | $174.97 | $31.90 |
| 52 Week High | $232.02 | $49.62 |
Technical Indicators
Market Signals| Indicator | AIZ | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 50.45 | 63.52 |
| Support Level | $219.53 | $43.00 |
| Resistance Level | $224.89 | $44.79 |
| Average True Range (ATR) | 3.67 | 1.03 |
| MACD | -0.87 | 0.06 |
| Stochastic Oscillator | 30.57 | 83.48 |
Price Performance
Historical ComparisonAbout AIZ Assurant Inc.
Assurant Inc is a protection company that partners with the brands to safeguard and service connected devices, homes and automobiles. It operate in North America, Latin America, Europe and Asia Pacific through two operating segments: Global Lifestyle and Global Housing. Global Lifestyle: includes mobile device solutions (including extended service contracts, insurance policies and related services), extended service contracts and related services for consumer electronics and appliances, and financial services and other insurance products. Global Housing: includes lender-placed homeowners, manufactured housing and flood insurance, as well as voluntary manufactured housing, condominium and homeowners insurance. Key revenue is generated from Global Lifestyle segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.